Compositions and methods for treating alzheimer's disease and parkinson's disease

Abstract

Pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt of azelastine, and methylcobalamin are disclosed. Methods of using the pharmaceutical compositions for treating patients with Alzheimer's disease or Parkinson's disease are also disclosed.

1 . A pharmaceutical composition, comprising:
 azelastine or a pharmaceutically acceptable salt of azelastine;   methylcobalamin;   and one or more pharmaceutically acceptable excipients.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount in the range of about 4 mg to about 24 mg. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the methylcobalamin is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 50 mg. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the methylcobalamin is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 10 mg. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein:
 the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount in the range of about 4 mg to about 24 mg; and   the methylcobalamin is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 50 mg.   
     
     
         6 . The pharmaceutical composition of  claim 2 , wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride. 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the methylcobalamin is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 50 mg. 
     
     
         8 . The pharmaceutical composition of  claim 6 , wherein the azelastine hydrochloride is present in an amount in the range of about 4 mg to about 18 mg. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated as a capsule, caplet, tablet, or pill capable of oral ingestion. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the pharmaceutical composition is formulated in a solid form or a liquid form. 
     
     
         11 . The pharmaceutical composition of  claim 6 , wherein the azelastine hydrochloride is present in the pharmaceutical composition in an amount ranging from about 4 mg to about 12 mg and the amount of methylcobalamin is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 5 mg. 
     
     
         12 . A pharmaceutical composition, comprising:
 azelastine or a pharmaceutically acceptable salt of azelastine;   methylcobalamin;   and one or more pharmaceutically acceptable excipients;   wherein the pharmaceutical composition is formulated as a tablet with a coating to delay disintegration until in a gastrointestinal tract.   
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein:
 the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount in the range of about 4 mg to about 24 mg; and   the methylcobalamin is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 50 mg.   
     
     
         14 . The pharmaceutical composition of  claim 12 , wherein:
 the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount in the range of about 4 mg to about 24 mg; and   wherein the methylcobalamin is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 10 mg.   
     
     
         15 . The pharmaceutical composition of  claim 12 , wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride. 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the azelastine hydrochloride is present in the pharmaceutical composition in an amount ranging from about 4 mg to about 12 mg and the amount of methylcobalamin is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 5 mg. 
     
     
         17 . The composition of  claim 12 , wherein:
 the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount that is 2, 3, 4, 5, 6, 7, 8, 9, or 10 times as much as the methylcobalamin; or   the methylcobalamin is present in the pharmaceutical composition in an amount that is 2, 3, 4, 5, 6, 7, 8, 9, or 10 times as much as the azelastine or the pharmaceutically acceptable salt of azelastine.   
     
     
         18 . A method comprising:
 administering to a patient having Alzheimer's disease or Parkinson's disease a capsule, caplet, tablet, or pill of a pharmaceutical composition formulated for oral ingestion, wherein the pharmaceutical composition comprises:
 azelastine or of a pharmaceutically acceptable salt of azelastine; 
 methylcobalamin; 
 and one or more pharmaceutically acceptable excipients. 
   
     
     
         19 . The method of  claim 18 , wherein:
 the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount in the range of about 4 mg to about 24 mg; and   the methylcobalamin is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 50 mg.   
     
     
         20 . The method of  claim 18 , wherein the pharmaceutical composition is formulated as a tablet with a coating to delay disintegration until in a gastrointestinal tract.